Figure 8
Effect of TGF-β1 on the expression of SA-β-Gal in HPMC. (a) Serum-stimulated early-passage HPMC were treated with various doses of TGF-β1 for 6 days and then analyzed for the presence of SA-β-Gal. Magnification × 40. (b) Percentage of cells expressing SA-β-Gal after the incubation in the presence of absence of TGF-β1. The means of three independent experiments with cells from different donors. Asterisks represent a significant difference compared with cells not exposed to TGF-β1. (c) HPMC were treated with 1?ng/ml of TGF-β1 for 5 days in the presence of either neutralizing anti-TGF-β1 antibody or control antibody. SA-β-Gal activity was measured in HPMC lysates by specific quantitative assay. The data represent the means of four independent experiments with cells from different donors. Asterisks represent a significant difference compared with cells not exposed to TGF-β1.
